Herpes simplex virus 1 (HSV-1) causes a number of clinical manifestations including cold sores, keratitis, meningitis and encephalitis. Although current drugs are available to treat HSV-1 infection, they can cause side effects such as nephrotoxicity. Moreover, owing to the emergence of drug-resistant HSV-1 strains, new anti-HSV-1 compounds are needed. Because many viruses exploit cellular host proteases and encode their own viral proteases for survival, we investigated the inhibitory effects of a panel of protease inhibitors (TLCK, TPCK, E64, bortezomib, or MG132) on HSV-1 replication and several host cell signaling pathways. We found that HSV-1 infection suppressed c-Raf-MEK1/2-ERK1/2-p90RSK signaling in host cells, which facilitated viral replication. The mechanism by which HSV-1 inhibited ERK signaling was mediated through the polyubiquitination and proteasomal degradation of Ras-guanine nucleotidereleasing factor 2 (Ras-GRF2). Importantly, the proteasome inhibitor MG132 inhibited HSV-1 replication by reversing ERK suppression in infected cells, inhibiting lytic genes (ICP5, ICP27 and UL42) expression, and overcoming the downregulation of Ras-GRF2. These results indicate that the suppression of ERK signaling via proteasomal degradation of Ras-GRF2 is necessary for HSV-1 infection and replication. Given that ERK activation by MG132 exhibits anti-HSV-1 activity, these results suggest that the proteasome inhibitor could serve as a novel therapeutic agent against HSV-1 infection. Herpes simplex virus 1 (HSV-1) is a member of the Alphaherpesvirinae subfamily and a human DNA virus that is known to cause a number of clinical manifestations, including cold sores, keratitis, meningitis and encephalitis 1,2. HSV-1 can establish latent infections in sensory neurons and periodically reactivate at the original site of infection, resulting in lesions 3. During latent infection, the HSV genome circularizes to form an episome in the nucleus, leading to expression of latency-associated transcripts (LATs) that are thought to be necessary for latency and reactivation. Upon reactivation, lytic-related genes are expressed in a temporal and sequential manner, which can be divided into three transcriptional stages: immediate early (IE/α), early (E/β), and late (L/γ). Some IE products function as triggers for transcriptional activation of E genes associated with viral DNA replication. L genes encode structural and functional proteins for producing viral progeny. Although acyclovir (ACV) and its analogues have been the standard therapy for HSV infection, their widespread and long-term use has recently led to the emergence of drug-resistant HSV strains 4-6. Thus, due to a lack of effective vaccines, side effects associated with ACV, such as nephrotoxicity, and appearance of ACV-resistant strains, new anti-HSV compounds with mechanisms of inhibition distinct from ACV are urgently needed for the treatment of HSV infection 7. HSV infection alters several signaling pathways, which can be triggered by viral molecules known as pathogen assoc...